ĐÁNH GIÁ kết QUẢ hóa xạ TRỊ TRƯỚC và hóa xạ ĐỒNG THỜI CARBOPLATIN HÀNG TUẦN UNG THƯ BIỂU mô vảy đầu cổ GIAI đoạn IVA IVB

BỘ GIÁO DỤC VÀ ĐÀO TẠO BỘ Y TẾ TRƯỜNG I HC Y H NI ============= LI MINH BCH ĐáNH GIá kết HóA xạ TRị TRƯớC Và HóA Xạ ĐồNG THờI carboplatin hàng tuần UNG THƯ BIểU MÔ VảY ĐầU Cổ GIAI ĐOạN IVA-IVB Chuyờn ngnh: Ung th Mó số: CK 62722301 LUẬN VĂN CHUYÊN KHOA CẤP II Người hướng dẫn khoa học: PGS.TS Ngô Thanh Tùng HÀ NỘI - 2018 LỜI CẢM ƠN Sau thời gian học tập công tác Trường Đại học Y Hà Nội, Bệnh viện K biết ơn kính trọng, em xin chân thành cảm ơn Các thầy, cô ban giám hiệu, môn ung thư trường Đại học Y Hà Nội Ban giám đốc bệnh viện K đồng nghiệp khoa xạ đầu cổ, khoa nội 2, khoa nội Qn Sứ giúp tơi hồn thành luận văn Đặc biệt, em xin bày tỏ lòng biết ơn sâu sắc tới: PGS.TS Ngô Thanh Tùng, người thầy trực tiếp hướng dẫn giúp đỡ em trình thực đề tài tận tình giúp đỡ em công việc sống; PGS.TS Nguyễn văn Hiếu, PGS.TS Lê văn Quảng giúp đỡ suốt trình học tập; Xin chân thành cảm ơn gia đình, bạn bè đồng nghiệp tạo điều kiện giúp đỡ nghiên cứu để hoàn thành đề tài này; Vợ con, lắng nghe, đồng cảm, động viên Tuy nhiên điều kiện lực thân hạn chế, chuyên đề nghiên cứu khoa học chắn không tránh khỏi thiếu sót Kính mong nhận đóng góp để nghiên cứu hoàn thiện Lại Minh Bách LỜI CAM ĐOAN Tôi Lại Minh Bách, học viên lớp chuyên khoa 2, chuyên ngành ung thư khóa 30, trường Đại học Y Hà Nội, xin cam đoan: Đây luận văn thân trực tiếp thực hướng dẫn PGS.TS Ngô Thanh Tùng Cơng trình khơng trùng lặp với nghiên cứu khác cơng bố Việt Nam Các số liệu thông tin nghiên cứu hồn tồn xác, trung thực khách quan, xác nhận chấp thuận sở nơi nghiên cứu Tơi xin hồn tồn chịu trách nhiệm trước pháp luật cam kết Hà Nội, ngày 02 tháng 09 năm 2018 Người viết Lại Minh Bách MỤC LỤC DANH MỤC BẢNG DANH MỤC BIỂU ĐỒ DANH MỤC HÌNH 10 ĐẶT VẤN ĐỀ Theo ước tính Hoa Kỳ, năm 2014 có 55.070 ca ung thư khoang miệng, họng, quản, chiếm 3% tổng số ca bệnh chẩn đoán khoảng 12.000 ca tử vong ung thư đầu cổ [1] Ung thư biểu mô vảy chiếm 90% thể mô bệnh học ung thư đầu cổ Khi bệnh giai đoạn tiến triển chỗ, vùng thường phải kết hợp phương thức điều trị Phẫu thuật cần xét định trước Nếu bệnh khơng định phẫu thuật cân nhắc: Xạ trị đơn triệt căn, hóa xạ đồng thời phác đồ có điều trị hóa chất cảm ứng (induction therapy) [2] Hiện nay, điều trị chuẩn cho ung thư biểu mơ vẩy vùng đầu cổ khơng mổ hóa xạ trị đồng thời hóa trị trước hóa xạ trị đồng thời [2] Theo hướng dẫn từ NCCN v 2.2017, pha hóa xạ đồng thời thường dùng hàng tuần carboplatin cetuximab Thử nghiệm lâm sàng pha III TAX 234 501 bệnh nhân ung thư biểu mô vảy (khoang miệng, họng miệng, quản, hạ họng) khơng mổ (T3,4 N2,3) chia hai nhóm Nhóm dùng hóa trị cảm ứng phác đồ TPF (Docetaxel, Cisplatin Fluorouracil) nhóm dùng phác đồ PF (Cisplatin, Fluorouracil) Sau đó, hai nhóm hóa xạ đồng thời với carboplatin hàng tuần xạ trị Thời gian theo dõi trung bình 72,2 tháng (95% CI 68,8-75,5) Sống thêm tồn tốt có ý nghĩa thống kê nhóm dùng TPF so với PF (hazard ratio [HR] 0,74; 95% CI 0,58-0,94), với sống thêm năm 52% nhóm dùng TPF 42% nhóm dùng PF Sống thêm trung bình 70,6 tháng (95% CI 49,0- 45 Vincent T Devita, Chu Edward (2016) Physicians' Cancer Chemotherapy Drug Manual 2016 Series,Jones & Bartlett Learning 46 (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group Am J Clin Oncol 5, 649-55 47 Response Evaluation Criteria in Solid Tumors (RECIST) Committee (2000), "Response Evaluation Criteria In Solid Tumors (RECIST)", Journal of the National Cancer Institute, 92(3), p 205-216 48 Nci http://ctep.cancer.gov2016 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#c tc_40 49 J B Vermorken, Remenar E., Van Herpen C., et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357(17), 1695-704 50 M R Posner, Hershock D M., Blajman C R., et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer N Engl J Med 357(17), 1705-15 51 D J Adelstein, Moon J., Hanna E., et al (2010) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216) Head Neck 32(2), 221-8 52 A Paccagnella, Ghi M G., Loreggian L., et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study Ann Oncol 21(7), 1515-22 53 J S Ahn, Cho S H., Kim O K., et al (2007) The efficacy of an induction chemotherapy combination with docetaxel, cisplatin, and 5-FU followed by concurrent chemoradiotherapy in advanced head and neck cancer Cancer Res Treat 39(3), 93-8 54 F P Worden, Moon J., Samlowski W., et al (2006) A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007 Cancer 107(2), 319-27 55 M Tsukuda, Ishitoya J., Matsuda H., et al (2010) Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck Cancer Chemother Pharmacol 66(4), 729-36 56 C S Kohn, Tsoh J Y., Weisner C M (2003) Changes in smoking status among substance abusers: baseline characteristics and abstinence from alcohol and drugs at 12-month follow-up Drug Alcohol Depend 69(1), 6171 57 Trần Văn Aaa Thiệp (2004) Điều trị ung thư quản giai đoạn III, IV Y học TP Hồ Chí Minh 8(Phụ số 4), 117-23 58 Từ Thị Thanh Aaa Hương (2006) Nghiên cứu hiệu phác đồ điều trị tân bổ trợ cisplatin 5Fluorouracil ung thư hạ họng, quản giai đoạn III-IV (Mo) bệnh viện K 2002-2005 Luận văn thạc sĩ Y học Trường Đại học Y Hà Nội 59 S A Bhide, Ahmed M., Barbachano Y., et al (2008) Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer Br J Cancer 99(1), 57-62 60 J K Salama, Stenson K M., Kistner E O., et al (2008) Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels Ann Oncol 19(10), 1787-94 61 J P Agarwal, Mallick I., Bhutani R., et al (2009) Prognostic factors in oropharyngeal cancer analysis of 627 cases receiving definitive radiotherapy Acta Oncol 48(7), 1026-33 62 R Hitt, Lopez-Pousa A., Martinez-Trufero J., et al (2005) Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer J Clin Oncol 23(34), 8636-45 63 Ngô Thanh Aaa Tùng (2011) Nghiên cứu số đặc điểm lâm sàng, cận lâm sàng kết hóa xạ gia tốc đồng thời ung thư hạ họng quản giai đoạn (III, IV) không mổ Bệnh viện K Trường Đại học Y Hà Nội Luận án tiến sĩ y học 64 Oreste Iocca, Farcomeni Alessio, Di Rocco Arianna, et al (2018) Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options Oral oncology 80, 40-51 65 Katarzyna J Jerzak, Santos Keemo Delos, Saluja Ronak, et al (2017) A network meta-analysis of the sequencing and types of systemic therapies with definitive radiotherapy in locally advanced squamous cell carcinoma of the head and neck (LASCCHN)☆ Oral oncology 71, 1-10 66 Jean-Pierre Pignon, Le Maitre Aurelie, Maillard Emilie, et al (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients Radiotherapy and Oncology 92(1), 4-14 67 Wilfried Budach, Bölke Edwin, Kammers Kai, et al (2016) Induction chemotherapy followed by concurrent radio-chemotherapy versus concurrent radio-chemotherapy alone as treatment of locally advanced squamous cell carcinoma of the head and neck (HNSCC): A meta-analysis of randomized trials Radiotherapy and Oncology 118(2), 238-43 68 Liat Vidal, Aharon Irit Ben, Limon Dror, et al (2017) Role of induction chemotherapy prior to chemoradiation in head and neck squamous cell cancer—systematic review and meta-analysis The Cancer Journal 23(2), 79-83 69 Robert Haddad, O'neill Anne, Rabinowits Guilherme, et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase trial The lancet oncology 14(3), 257-64 70 Zhang Xp Chen Jw, Zheng Jk, Et Al (2011) A randomized control trial of induction chemotherapy combined with concurrent chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma J Chongqing Med Univ 36, 11103–6 71 Jie Ma, Liu Ying, Yang Xi, et al (2013) Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a metaanalysis World journal of surgical oncology 11(1), 67 72 Gali Perl, Ben-Aharon Irit, Popovtzer Aron, et al (2013) Addition of taxane to induction therapy in head and neck malignancies: a systematic review and meta-analysis of randomized controlled trials Chemotherapy 59(6), 435-40 73 Yoann Pointreau, Garaud Pascal, Chapet Sophie, et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation Journal of the National Cancer Institute 101(7), 498-506 74 S Michiels, Le Mtre A, Buyse M, et al (2009) MARCH and MACHNC Collaborative Groups Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data Lancet Oncol 10(4), 341-50 75 Ezra Ew Cohen, Karrison Theodore G, Kocherginsky Masha, et al (2014) Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer Journal of clinical oncology 32(25), 2735 76 A Paccagnella, Ghi Mg, Loreggian L, et al (2009) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study Annals of oncology 21(7), 1515-22 77 R Hitt, Grau Jj, López-Pousa A, et al (2014) Spanish Head and Neck Cancer Cooperative Group (TTCC) A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer Ann Oncol 25(1), 216-25 78 Ri Haddad, Posner M, Hitt R, et al (2018) Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions Annals of Oncology 29(5), 1130-40 79 Naoki Izawa, Onozawa Yusuke, Hikosaka Tomomi, et al (2015) Efficacy and feasibility of docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy for locally advanced head and neck squamous cell carcinoma classified as clinical nodal stage N2c, N3, or N2b with supraclavicular lymph node metastases International journal of clinical oncology 20(3), 455-62 80 Vincent Grégoire, Lefebvre J-L, Licitra L, et al (2010) Squamous cell carcinoma of the head and neck: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up Annals of oncology 21(suppl_5), v184-v6 81 A Kreeft, Tan Ib, Van Den Brekel Mwm, et al (2009) The surgical dilemma of ‘functional inoperability’in oral and oropharyngeal cancer: current consensus on operability with regard to functional results Clinical Otolaryngology 34(2), 140-6 82 William M Lydiatt, Patel Snehal G, O'sullivan Brian, et al (2017) Head and neck cancers—major changes in the American Joint Committee on cancer eighth edition cancer staging manual CA: a cancer journal for clinicians 67(2), 122-37 83 Maria Grazia Ghi, Paccagnella A, Ferrari D, et al (2017) Induction TPF followed by concomitant treatment versus concomitant treatment alone in locally advanced head and neck cancer A phase II–III trial Annals of Oncology 28(9), 2206-12 84 Krzysztof Misiukiewicz, Gupta Vishal, Posner Marshall The Italian Collaborative Group sets a standard for the treatment of locally advanced head and neck cancer Oxford University Press; 2017 85 Department of Veterans Affairs Laryngeal Cancer Study Group* (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer New England Journal of Medicine 324(24), 1685-90 86 Monica B Spaulding, Fischer Susan G, Wolf Gregory T (1994) Tumor response, toxicity, and survival after neoadjuvant organ-preserving chemotherapy for advanced laryngeal carcinoma The Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group Journal of Clinical Oncology 12(8), 1592-9 87 Marco Merlano, Rosso Riccardo, Sertoli Mario Roberto, et al (1990) Randomized comparison of two chemotherapy, radiotherapy schemes for stage III and IV unresectable squamous cell carcinoma of the head and neck The Laryngoscope 100(5), 531-5 88 Jl Lefebvre, Rolland F, Tesselaar M, et al (2009) Phase randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy Journal of the National Cancer Institute 101(3), 142-52 89 Guillaume Janoray, Pointreau Yoann, Garaud Pascal, et al Long-term results of GORTEC 2000-01: A multicentric randomized phase III trial of induction chemotherapy with cisplatin plus 5-fluorouracil, with or without docetaxel, for larynx preservation American Society of Clinical Oncology; 2015 90 Arlene A Forastiere, Zhang Qiang, Weber Randal S, et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer Journal of clinical oncology 31(7), 845 91 Adriano Paccagnella, Orlando Antonio, Marchiori Carlo, et al (1994) Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo JNCI: Journal of the National Cancer Institute 86(4), 265-72 92 B Henriques De Figueiredo, Fortpied Catherine, Menis Jessica, et al (2016) Long-term update of the 24954 EORTC phase III trial on larynx preservation European Journal of Cancer 65, 109-12 93 David E Schuller, Stem David W, Metch Barbara, et al (1988) Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group The Laryngoscope 98(11), 1205-11 94 A Villar, Pera J, Arellano A, et al (1987) Induction chemotherapy with cisplatin, bleomycin and methotrexate in advanced head and neck cancer— lack of therapeutic gain Radiotherapy and Oncology 10(3), 175-81 95 C Domenge, Hill C, Lefebvre Jl, et al (2000) Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma British journal of cancer 83(12), 1594 96 Marshall R Posner, Hershock Diane M, Blajman Cesar R, et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer New England Journal of Medicine 357(17), 1705-15 97 Katharine Ar Price, Cohen Ezra E (2012) Current treatment options for metastatic head and neck cancer Current treatment options in oncology 13(1), 35-46 98 Gustavo N Marta, Riera Rachel, Bossi Paolo, et al (2015) Induction chemotherapy prior to surgery with or without postoperative radiotherapy for oral cavity cancer patients: systematic review and meta-analysis European Journal of Cancer 51(17), 2596-603 99 P Bossi, Lo Vullo S, Guzzo M, et al (2014) Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial Annals of oncology 25(2), 462-6 100 Jean Louis Lefebvre, Pointreau Yoann, Rolland Frederic, et al (2013) Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: the TREMPLIN randomized phase II study J Clin Oncol 31(7), 853-9 101 Shanthi Marur, Li Shuli, Cmelak Anthony J, et al (2017) E1308: phase II trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx—ECOG-ACRIN Cancer Research Group Journal of Clinical Oncology 35(5), 490 102 Cml Driessen, De Boer Jp, Gelderblom H, et al (2016) Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study)(Dutch Head and Neck Society 08-01): a randomized phase II study European journal of cancer 52, 77-84 103 Volker Budach (2010) TPF sequential therapy: when and for whom? The Oncologist 15(Supplement 3), 13-8 104 K Kian Ang, Zhang Qiang, Rosenthal David I, et al (2014) Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522 Journal of clinical oncology 32(27), 2940 105 Joanne B Weidhaas, Harris Jonathan, Schaue Dörthe, et al (2017) The KRAS-variant and cetuximab response in head and neck squamous cell cancer: a secondary analysis of a randomized clinical trial JAMA oncology 3(4), 483-91 106 Fausto Petrelli, Coinu Andrea, Riboldi Valentina, et al (2014) Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and metaanalysis of published studies Oral oncology 50(11), 1041-8 107 Jian Guan, Li Qinyang, Zhang Yue, et al (2016) A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN) Oncotarget 7(6), 7110 108 Jingwen Huang, Zhang Jing, Shi Changle, et al (2016) Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis BMC cancer 16(1), 689 PHỤ LỤC THUẬT NGỮ CHUNG VỀ CÁC BIẾN CỐ BẤT LỢI (CTCAE 4.03) Độ Thiếu máu Độ Hemoglobin (Hgb) Hgb